



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE

7th Edition

---

# CLSI VET01S™

## Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

CLSI VET01S includes updated tables for the Clinical and Laboratory Standards Institute  
veterinary antimicrobial susceptibility testing standard VET01.

---

A CLSI supplement for global application.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

## Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

Dubraska V. Diaz-Campos, DVM, PhD  
Brian V. Lubbers, DVM, PhD, DACVCP  
Stefan Schwarz, DVM  
Robert Bowden, BS  
Claire R. Burbick, DVM, PhD, DACVM  
Merran Govendir, PhD, BVSc, FHERDSA,  
MANZCVSc  
Scott B. Killian, BS  
Sara D. Lawhon, DVM, PhD, DACVM  
Xian-Zhi Li, PhD

Kelli Maddock, MS, MLS(ASCP)M  
Ron A. Miller, PhD, MS  
Ian Morrissey, BSc, MBA, PhD, FRSM  
K. Marcia Murphy, DVM, DACVD  
Mark G. Papich, DVM, MS  
Michael T. Sweeney, MS  
Ronald Tessman, DVM, PhD, DACVIM,  
DACVPM  
S. Steve Yan, PhD

### Abstract

The data in the tables are valid only if the methodologies in CLSI VET01<sup>1</sup> are followed. CLSI VET01<sup>1</sup> contains information about disk and dilution susceptibility test procedures for aerobic and facultatively anaerobic bacteria. Clinicians need information from the microbiology laboratory for treating and/or confirming treatment decisions for their patients with bacterial infections and depend heavily on this information for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to interpret results based on the most current breakpoints and interpretive categories for antimicrobial agents used in veterinary medicine.

The tables presented in CLSI VET01S represent the most current information for drug selection, interpretation, and QC using the procedures standardized in CLSI VET01.<sup>1</sup> Users should replace previously published tables with these new tables. Changes to the tables since the previous edition appear in black boldface type.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals*. 7th ed. CLSI supplement VET01S (ISBN 978-1-68440-210-6 [Print]; ISBN 978-1-68440-211-3 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2024.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current edition of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one,  
or to request a copy of the catalog, contact us at:**

**T:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@clsi.org](mailto:customerservice@clsi.org) **W:** [www.clsi.org](http://www.clsi.org)



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

Copyright ©2024 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, or other product or material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

To read CLSI's full Copyright Policy, please visit our website at <https://clsi.org/terms-of-use/>.

### Suggested Citation

CLSI. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals*. 7th ed. CLSI supplement VET01S. Clinical and Laboratory Standards Institute; 2024.

### Previous Editions:

May 2004, July 2013, June 2015, June 2018, October 2020, February 2023

CLSI VET01-Ed6-S-Ed7  
ISBN 978-1-68440-210-6 (Print)  
ISBN 978-1-68440-211-3 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

Volume 44, Number 2

## Committee Membership

### Subcommittee on Veterinary Antimicrobial Susceptibility Testing

<b>Dubrasca V. Diaz-Campos, DVM, PhD</b> Chairholder College of Veterinary Medicine, Veterinary Medical Center, The Ohio State University USA	<b>Merran Govendir, PhD, BVSc,</b> FHERDSA, MANZCVSc The University of Sydney Australia	<b>Ian Morrissey, BSc, MBA, PhD,</b> FRSM Antimicrobial Focus Ltd. United Kingdom
<b>Brian V. Lubbers, DVM, PhD, DACVCP</b> Vice-Chairholder Kansas State University USA	<b>Scott B. Killian, BS</b> Thermo Fisher Scientific USA	<b>K. Marcia Murphy, DVM, DACVD</b> North Carolina State University, College of Veterinary Medicine USA
<b>Stefan Schwarz, DVM</b> Committee Secretary Freie Universität Berlin Germany	<b>Sara D. Lawhon, DVM, PhD, DACVM</b> Texas A&M University USA	<b>Michael T. Sweeney, MS</b> Zoetis USA
<b>Claire R. Burbick, DVM, PhD, DACVM</b> Washington State University USA	<b>Xian-Zhi Li, PhD</b> Health Canada Veterinary Drugs Directorate Canada	<b>Ronald Tesse, DVM, PhD,</b> DACVIM, DACVPP Elanco Animal Health USA
	<b>Ron A. Miller, PhD, MS</b> FDA Center for Veterinary Medicine USA	

### Working Group on Editorial/VAST Breakpoint Tables

<b>Claire R. Burbick, DVM, PhD,</b> DACVM Washington State University Chairholder USA	<b>Merran Govendir, PhD, BVSc,</b> FHERDSA, MANZCVSc The University of Sydney Australia	<b>Ron A. Miller, PhD, MS</b> FDA Center for Veterinary Medicine USA
<b>Robert Bowden, BS</b> Committee Secretary Beth Israel Deaconess Medical Center USA	<b>Sara D. Lawhon, DVM, PhD, DACVM</b> Texas A&M University USA	<b>Mark G. Papich, DVM, MS</b> College of Veterinary Medicine, North Carolina State University USA
<b>Dubrasca V. Diaz-Campos, DVM, PhD</b> College of Veterinary Medicine, Veterinary Medical Center, The Ohio State University USA	<b>Xian-Zhi Li, PhD</b> Health Canada Veterinary Drugs Directorate Canada	<b>Stefan Schwarz, DVM</b> Freie Universität Berlin Germany
	<b>Kelli Maddock, MS, MLS(ASCP)M</b> NDSU Veterinary Diagnostic Laboratory USA	<b>Michael T. Sweeney, MS</b> Zoetis USA
		<b>S. Steve Yan, PhD</b> FDA Center for Veterinary Medicine USA

## Working Group on Generic Drugs

Mark G. Papich, DVM, MS  
Chairholder  
College of Veterinary Medicine,  
North Carolina State University  
USA

Cory Langston, DVM, PhD  
Vice-Chairholder  
Mississippi State University  
USA

Stefan Schwarz, DVM  
Committee Secretary  
Freie Universität Berlin  
Germany

Robert Bowden, BS  
Beth Israel Deaconess Medical Center  
USA

Virginia R. Fajt, DVM, PhD, DACVCP  
Texas A&M University  
USA

Merran Govendir, PhD, BVSc, FHERDSA,  
MANZCVSc  
The University of Sydney  
Australia

Lacie Gunnett, BS  
Zoetis  
USA

Marilyn N. Martinez, PhD  
FDA Center for Veterinary  
Medicine  
USA

Shabbir Simjee, MSc, PhD  
Elanco Animal Health  
United Kingdom

John D. Turnidge, M.V.M., BS,  
FRACP, FASM, FRCPA  
The University of Adelaide  
Australia

## Staff

Clinical and Laboratory  
Standards Institute  
USA

Lori T. Selden, MS, MLS(ASCP)  
*Senior Program Manager*

Laura Martin  
*Editorial Manager*

Catherine E.M. Jenkins, ELS  
*Editor*

Christy J. Leirer, MS  
*Editor*

Lisa M.W. Walker, MS, ELS  
*Editor*

## Contents

Abstract .....	i
Committee Membership.....	iii
Overview of Changes .....	viii
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges.....	xix
CLSI Reference Methods vs Commercial Methods and CLSI vs Regulatory Authority Breakpoints.....	xi
CLSI Veterinary-Specific Breakpoint Additions and Revisions Since the Previous Edition .....	xxi
CLSI Subcommittee on Veterinary Antimicrobial Susceptibility Testing Mission Statement and Responsibilities .....	xxiii
Instructions for Use of Tables.....	1
References .....	17
Table 1. Antimicrobial Agents That Could Be Considered for Routine Testing by Veterinary Microbiology Laboratories .....	18
Table 2A. Zone Diameter and MIC Breakpoints for Enterobacterales .....	24
Table 2B. Zone Diameter and MIC Breakpoints for <i>Pseudomonas aeruginosa</i> .....	42
Table 2C-1. Zone Diameter and MIC Breakpoints for <i>Staphylococcus</i> spp. for B-Lactams and B-Lactam Combination Agents.....	48
Table 2C-2. Zone Diameter and MIC Breakpoints for <i>Staphylococcus</i> spp. for Non-B-Lactams .....	58
Table 2D. Zone Diameter and MIC Breakpoints for <i>Enterococcus</i> spp. ....	70
Table 2E. Zone Diameter and MIC Breakpoints for <i>Streptococcus</i> spp. ....	78
Table 2F. Zone Diameter and MIC Breakpoints for <i>Bordetella bronchiseptica</i> .....	92
Table 2G. Zone Diameter and MIC Breakpoints for <i>Mannheimia haemolytica</i> .....	94
Table 2H. Zone Diameter and MIC Breakpoints for <i>Pasteurella multocida</i> .....	96
Table 2I. Zone Diameter and MIC Breakpoints for <i>Actinobacillus</i> spp.....	100
Table 2J. Zone Diameter and MIC Breakpoints for <i>Histophilus somni</i> .....	104
.....	

**Contents (Continued)**

Table 2K. Zone Diameter and MIC Mastitis (Intramammary Infection) Breakpoints for Enterobacterales .....	106
Table 2L. Zone Diameter and MIC Mastitis (Intramammary Infection) Breakpoints for <i>Staphylococcus</i> spp. ....	110
Table 2M. Zone Diameter and MIC Mastitis (Intramammary Infection) Breakpoints for <i>Streptococcus</i> spp. ....	110
Table 3. QC Strain Culture Collection Numbers for Antimicrobial Susceptibility Tests ..	122
Table 4A. Zone Diameter QC Ranges for Nonfastidious Organisms .....	124
Table 4B. Zone Diameter QC Ranges for Fastidious Organisms.....	128
Table 4C. Zone Diameter QC Ranges for <i>Campylobacter jejuni</i> ATCC® 33560 .....	130
Table 4D. Disk Diffusion Reference Guide to QC Frequency .....	132
Table 4E. Disk Diffusion Troubleshooting Guide .....	134
Table 5A. MIC QC Ranges for Nonfastidious Organism .....	138
Table 5B. MIC QC Ranges for Fastidious Organisms (Broth Dilution Methods).....	140
Table 5C. MIC QC Ranges for <i>Campylobacter jejuni</i> ATCC® 33560.....	142
Table 5D. MIC QC Ranges for Anaerobes (Broth Dilution Method).....	144
Table 5E. MIC QC Ranges for Anaerobes (Broth Microdilution Method) .....	146
Table 5F. MIC Reference Guide to QC Frequency .....	148
Table 5G. MIC Troubleshooting Guide .....	150
Table 6. Solvents and Diluents for Preparing Stock Solutions of Antimicrobial Agents....	156
Table 7A. Tests for Extended-Spectrum B-Lactamases in <i>Klebsiella pneumoniae</i> , <i>Klebsiella oxytoca</i> , <i>Escherichia coli</i> , and <i>Proteus mirabilis</i> .....	158
Introduction to Tables 7B and 7C. Tests for Carbapenemases in Enterobacterales and <i>Pseudomonas aeruginosa</i> .....	164
Table 7B. Carba NP Test for Suspected Carbapenemase Production in Enterobacterales and <i>Pseudomonas aeruginosa</i> .....	166
Table 7C. Modified Carbapenem Inactivation Methods for Suspected Carbapenemase Production in Enterobacterales and <i>Pseudomonas aeruginosa</i> .....	174

## Contents (Continued)

Table 7D. Tests for Detecting $\beta$ -Lactamase Production in <i>Staphylococcus</i> spp. ....	186
Table 7E. Disk Diffusion Test for Prediction of <i>mecA</i> -Mediated Resistance in <i>Staphylococcus</i> spp. ....	190
Table 7F. Vancomycin Agar Screen for <i>Staphylococcus aureus</i> and <i>Enterococcus</i> spp. ....	192
Table 7G. Tests for Detecting Inducible Clindamycin Resistance in <i>Staphylococcus</i> spp., <i>Streptococcus</i> spp. B-Hemolytic Group, and <i>Streptococcus pneumoniae</i> . ....	194
Table 7H. Tests for Detecting High-Level Aminoglycoside Resistance in <i>Enterococcus</i> spp. (Includes Disk Diffusion) ....	196
Appendix A. Suggestions for Confirming Resistant, Intermediate, or Nonsusceptible Antimicrobial Susceptibility Test Results and Organism Identification ....	198
Appendix B. Intrinsic Resistance ....	204
Appendix C. QC Strains for Antimicrobial Susceptibility Tests ....	214
Appendix D. Sources of Antimicrobial Agent Disks ....	218
Appendix E. Dosage Regimens Used to Establish Susceptible or Susceptible-Dose Dependent Veterinary-Specific Breakpoints ....	220
Appendix F. Susceptible-Dose Dependent Interpretive Category ....	232
Appendix G. Epidemiological Cutoff Values ....	238
Appendix H. CLSI Veterinary-Specific Breakpoint Additions/Revisions to CLSI VET01 Supplements Since 1999 ....	242
Glossary I. Antimicrobial Class and Subclass Designations, Antimicrobial Agents, and Antimicrobial Resistance Mechanisms ....	252
Glossary II. Abbreviations Commonly Used for Antimicrobial Agents Incorporated Into Disks or Susceptibility Panels ....	256
Glossary III. List of Identical Abbreviations Used for More Than One Antimicrobial Agent in U.S. Diagnostic Products. ....	258
The Quality Management System Approach ....	260

.....

## Overview of Changes

CLSI VET01S-Ed7 replaces the previous edition of the supplement, CLSI VET01S-Ed6, published in February 2023. The major changes in CLSI VET01S-Ed7 are listed below. Other minor or editorial changes were made to the general formatting and to some of the table footnotes and comments. Changes to the tables since the previous edition appear in black boldface type. The following are additions or changes unless otherwise noted as a “*deletion*.”

- **General:**
  - Added susceptible-dose dependent (SDD) definition in Instructions for Use of Tables
  - Added “SDD” subcolumn in Tables 2A, 2B, and 2C-2 under “Interpretive Categories and MIC Breakpoints,  $\mu\text{g}/\text{mL}$ ” column
  - Revised body site entries in Tables 2A through 2L and Appendixes E and F from “urinary tract infection (UTI)” to “(lower) urinary tract (ur)”
  - Revised order of Appendixes C through H to align with order of appendixes in CLSI M100<sup>2</sup>
- **CLSI Veterinary-Specific Breakpoint Additions and Revisions Since the Previous Edition (p. xxi):**
  - Updated table to reflect breakpoint additions and revisions since CLSI VET01S-Ed6
- **Instructions for Use of Tables:**
  - Section II. Breakpoints and Interpretive Category Definitions (p. 4):
    - Section II.A, Breakpoint Definition:
      - Revised breakpoint definition to include “susceptible-dose dependent” interpretive category
    - Section II.B, Interpretive Category Definition (p. 4):
      - Revised interpretive category (for breakpoints) definition:
        - In NOTE 2, added “susceptible-dose dependent”
        - In EXAMPLE table, added “susceptible-dose dependent” row with minimal inhibitory concentration (MIC) and zone diameter breakpoints
        - In paragraph under EXAMPLE table, added “and susceptible-dose dependent”
        - In bulleted list under EXAMPLE table, added SDD definition
    - Section II.C, Example of Breakpoints and Interpretive Categories as Used in Tables 2 (p. 6):
      - In example table, added footnote a to the “intermediate (I)” column for zone diameter and MIC breakpoints
      - In paragraph under table:
        - Noted that some agents have an SDD breakpoint instead of an intermediate breakpoint
        - Added another reason why only MIC breakpoints may be available
  - Section III. Reporting Results (p. 6):
    - Section III.A, Organisms Included in Tables 2:
      - Added interpretive category result SDD
      - Clarified that interpretive category results facilitate understanding of the MIC value by clinicians
      - Updated reference for more information on epidemiological cutoff values (ECVs) from CLSI M100<sup>2</sup> to CLSI VET01S Appendix G